ES3013994T3 - Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders - Google Patents

Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders Download PDF

Info

Publication number
ES3013994T3
ES3013994T3 ES20185268T ES20185268T ES3013994T3 ES 3013994 T3 ES3013994 T3 ES 3013994T3 ES 20185268 T ES20185268 T ES 20185268T ES 20185268 T ES20185268 T ES 20185268T ES 3013994 T3 ES3013994 T3 ES 3013994T3
Authority
ES
Spain
Prior art keywords
compound
ethyl
mmol
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20185268T
Other languages
English (en)
Spanish (es)
Inventor
Werneck Guimarães Cristiano Ruch
Zaneti De Azevedo Hatylas Felype
Alessandra Mascarello
Da Costa Renata Watanabe
Torres Russo Valter Freire
De Souza Russo Elisa Mannochio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ache Laboratorios Farmaceuticos SA
Original Assignee
Ache Laboratorios Farmaceuticos SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos SA filed Critical Ache Laboratorios Farmaceuticos SA
Application granted granted Critical
Publication of ES3013994T3 publication Critical patent/ES3013994T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES20185268T 2016-10-24 2017-10-23 Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders Active ES3013994T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102016024814A BR102016024814A2 (pt) 2016-10-24 2016-10-24 composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono

Publications (1)

Publication Number Publication Date
ES3013994T3 true ES3013994T3 (en) 2025-04-16

Family

ID=62023150

Family Applications (2)

Application Number Title Priority Date Filing Date
ES20185268T Active ES3013994T3 (en) 2016-10-24 2017-10-23 Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
ES17865155T Active ES2970546T3 (es) 2016-10-24 2017-10-23 Compuestos, procedimiento para obtener los compuestos, composición farmacéutica, uso de los compuestos y método para tratar trastornos psiquiátricos y/o trastornos del sueño

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17865155T Active ES2970546T3 (es) 2016-10-24 2017-10-23 Compuestos, procedimiento para obtener los compuestos, composición farmacéutica, uso de los compuestos y método para tratar trastornos psiquiátricos y/o trastornos del sueño

Country Status (20)

Country Link
US (2) US10781182B2 (cg-RX-API-DMAC7.html)
EP (2) EP3741760B1 (cg-RX-API-DMAC7.html)
JP (1) JP7194683B2 (cg-RX-API-DMAC7.html)
KR (1) KR102594251B1 (cg-RX-API-DMAC7.html)
CN (2) CN110088092B (cg-RX-API-DMAC7.html)
AR (1) AR109467A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017351756B2 (cg-RX-API-DMAC7.html)
BR (1) BR102016024814A2 (cg-RX-API-DMAC7.html)
CL (1) CL2019001105A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019004756A2 (cg-RX-API-DMAC7.html)
DK (1) DK3529234T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP19032963A (cg-RX-API-DMAC7.html)
ES (2) ES3013994T3 (cg-RX-API-DMAC7.html)
FI (1) FI3529234T3 (cg-RX-API-DMAC7.html)
MX (1) MX392990B (cg-RX-API-DMAC7.html)
PE (2) PE20250558A1 (cg-RX-API-DMAC7.html)
PT (1) PT3529234T (cg-RX-API-DMAC7.html)
SG (2) SG11201903113TA (cg-RX-API-DMAC7.html)
UY (2) UY37334A (cg-RX-API-DMAC7.html)
WO (1) WO2018076090A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3433256T (lt) 2016-10-24 2019-11-11 Astrazeneca Ab 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izochinolino darinys, naudingas vėžio gydymui
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
MA52555A (fr) 2017-01-30 2021-03-17 Astrazeneca Ab Modulateurs du récepteur des oestrogènes
AR121842A1 (es) * 2020-04-15 2022-07-13 Ache Laboratorios Farmaceuticos Sa Compuesto de benzimidazol para el tratamiento de trastornos metabólicos
EP4138834A1 (en) 2020-04-24 2023-03-01 Astrazeneca AB Dosage regimen for the treatment of cancer
IL297218A (en) 2020-04-24 2022-12-01 Astrazeneca Ab Pharmaceutical formulations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5260051A (en) 1990-12-17 1993-11-09 Lever Brothers Company, Division Of Conopco, Inc. Compositions comprising phosphate ester compounds containing a beneficial reagent component
FR2674524B1 (fr) 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680366B1 (fr) 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
JP3559045B2 (ja) * 1994-06-10 2004-08-25 ナウチノ−イススレドバテルスキ インスティテュト ファルマコロギイ ロスシイスコイ アカデミイ メディツィンスキフ ナウク 薬理学的活性を有する2−メルカプトベンズイミダゾール誘導体
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
FR2738818B1 (fr) 1995-09-18 1997-12-05 Valentonine Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
PT1027043E (pt) 1996-12-10 2005-02-28 Bristol Myers Squibb Co Benzodioxole benzofurano di-hidrobenzofurano e benzodioxano como agentes melatonergicos
AU740554B2 (en) 1998-06-05 2001-11-08 Bristol-Myers Squibb Company Heterocyclic cis cyclopropane derivatives as melatonergic agents
ATE257834T1 (de) 1999-06-30 2004-01-15 Bristol Myers Squibb Co Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe
WO2003062224A1 (en) * 2002-01-17 2003-07-31 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
EP1719761A4 (en) * 2004-02-23 2007-10-10 Dainippon Sumitomo Pharma Co NEW HETEROCYCLIC CONNECTION
ES2264641B1 (es) * 2005-06-17 2008-03-01 Quimica Sintetica, S.A. Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios.
EP2114897A2 (en) 2006-09-12 2009-11-11 Pfizer Products Inc. Benzimidazolone derivatives
EP2088861A4 (en) 2006-10-25 2010-07-07 Takeda Pharmaceutical Benzimidazole compounds
RU2401831C2 (ru) 2008-12-15 2010-10-20 Алла Хем, Ллс Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono

Also Published As

Publication number Publication date
US20200277265A1 (en) 2020-09-03
US10781182B2 (en) 2020-09-22
UY40644A (es) 2024-02-29
BR112019008197A2 (pt) 2019-07-16
EP3741760A1 (en) 2020-11-25
ECSP19032963A (es) 2019-05-31
EP3741760B1 (en) 2024-12-04
SG10202009001TA (en) 2020-10-29
PE20191046A1 (es) 2019-08-06
WO2018076090A1 (en) 2018-05-03
MX392990B (es) 2025-03-24
US11091445B2 (en) 2021-08-17
CN115181108A (zh) 2022-10-14
EP3529234A1 (en) 2019-08-28
AU2017351756A1 (en) 2019-05-09
KR20190066023A (ko) 2019-06-12
JP7194683B2 (ja) 2022-12-22
US20190270711A1 (en) 2019-09-05
MX2019004782A (es) 2019-10-09
SG11201903113TA (en) 2019-05-30
KR102594251B1 (ko) 2023-10-25
PE20250558A1 (es) 2025-02-24
UY37334A (es) 2018-04-30
CN110088092B (zh) 2022-10-04
CO2019004756A2 (es) 2019-05-21
CA3042040A1 (en) 2018-05-03
CL2019001105A1 (es) 2019-09-06
PT3529234T (pt) 2024-02-01
CN110088092A (zh) 2019-08-02
AU2017351756B2 (en) 2022-01-27
FI3529234T3 (fi) 2023-12-28
EP3529234A4 (en) 2020-03-11
EP3741760C0 (en) 2024-12-04
ES2970546T3 (es) 2024-05-29
EP3529234B1 (en) 2023-11-29
AR109467A1 (es) 2018-12-12
JP2019537624A (ja) 2019-12-26
BR102016024814A2 (pt) 2018-05-08
DK3529234T3 (da) 2024-02-05

Similar Documents

Publication Publication Date Title
ES3013994T3 (en) Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
CA2924141A1 (en) 5-amino 4-cyano substituted oxazole and thiazole derivatives as inhibitors of human 12/15-lipoxygenase
CN116354901A (zh) 一种噻唑烷二酮类化合物及其制备方法和应用
CN117069696B (zh) 一种双靶点小分子抑制剂及其制备方法和应用
ES2866324T3 (es) Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria
KR20040015270A (ko) 축합 환식기를 가지는 환상 디아민 화합물
CN111205244B (zh) 噻唑并环类化合物、其制备方法、中间体和应用
JP2025511343A (ja) N-置換キノリノン化合物、その製造方法及びその使用
CA3042040C (en) 2-substituted benzimidazolyl compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
EP1544201B1 (en) Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications
KR20070087644A (ko) 도파민-d2 수용체 및 세로토닌 재흡수 위치에 대한친화도를 함께 갖는 벤즈디옥산 피페라진 유도체
BR112019008197B1 (pt) Composto, processo de obtenção do composto, composição farmacêutica e uso do composto
HK40081925A (en) Compounds, and preparation process, pharmaceutical composition and use thereof
WO2014062204A1 (en) Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases
HK40011198B (en) Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
HK40011198A (en) Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
US20060122175A1 (en) Benzdioxane piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
CN120230029A (zh) 整合素α4β7拮抗剂化合物及其制备方法与应用
WO2022257894A1 (zh) P300抑制剂及其在医药上的应用
CN116693470A (zh) 组胺h3受体抑制剂及其医药用途
CA2587936A1 (en) Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites
JPH11315071A (ja) ベンズイミダゾール誘導体
BR112018012828B1 (pt) Composto tetra-hidropiranil amino-pirrolpirimidinona, composição farmacêutica e uso dos mesmos